Please login to the form below

Not currently logged in
Email:
Password:

NDA Group appoints new vice president

Dr Werner Van den Eynde will also lead its advisory board

Regulatory affairs consultancy group NDA has appointed Dr Werner Van den Eynde as its new vice president to head up its advisory board providing strategic advice to pharmaceutical clients during its drug development life cycle.

Eynde comes to the Swiss group with international pharmaceutical experience, having held senior positions for the likes of GE Healthcare, Abbott and Solvay Pharmaceuticals.

His new role will see him manage strategy operations and development of the NDA advisory board, including business development, sales, marketing and service development.

He said: “NDA is the perfect platform for anyone who wants to have a positive impact on drug development across the world and the excellent reputation of the NDA advisory board is wide spread.

“Building on an almost twenty year tradition of unbiased advice to drug developing companies, I’m very motivated to continue the NDA success story and expand the advisory board to meet the future demands that science, technology and the regulatory environment put on companies developing therapies for patients.”

Eynde joins the group from Chemo – Exeltis where he was head of R&D, regulatory affairs and pharmacovigilance.

Johan Stromquist, chief executive officer, NDA Group, said: “ With his [Eynde] experience in drug development, following the process from many perspectives, he will be able to add tremendous value to clients in all stages of development, as well as create tailored teams and services of great benefit to the drug development industry.”

6th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics